Mineralys Therapeutics, Inc. () Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.05 M

Shareholding (Mar 2025)

FII

23.35%

Held by 47 FIIs

DII

25.92%

Held by 19 DIIs

Promoter

39.26%

How big is Mineralys Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Mineralys Therapeutics, Inc. has a market capitalization of 898.12 million and reported net sales of 0.00 million with a net profit of -188.51 million over the latest four quarters. Shareholder's funds were 191.26 million, and total assets amounted to 205.90 million as of Dec 24.

What does Mineralys Therapeutics, Inc. do?

22-Jun-2025

Mineralys Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $42 million and a market cap of $898.12 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -55.19%.

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, Mineralys Therapeutics, Inc. has a mildly bullish technical trend, supported by bullish daily moving averages and a weekly MACD, despite bearish RSI conditions and a significant year-to-date return of 208.77% compared to the S&P 500's 14.18%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,734 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.04

Return on Equity

-60.84%

Price to Book

8.72

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

-43 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

33.03%

6 Months

140.48%

1 Year

202.33%

2 Years

440.42%

3 Years

0.0%

4 Years

0.0%

5 Years

0.0%

Mineralys Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Mineralys Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD indicates a bullish stance, while the RSI shows bearish conditions for both weekly and monthly periods. The Bollinger Bands reflect a mildly bullish trend on the weekly and a bullish trend on the monthly. Daily moving averages are bullish, but the KST is mildly bearish on the weekly. Dow Theory and OBV show no trend in both weekly and monthly analyses. In terms of performance, the stock has returned 208.77% year-to-date and 173.85% over the past year, significantly outperforming the S&P 500, which returned 14.18% and 17.82% respectively. Overall, the current technical stance is mildly bullish, driven primarily by the bullish daily moving averages and the weekly MACD....

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

As of 3 October 2025, the technical trend for Mineralys Therapeutics, Inc. has changed from bullish to mildly bullish. The weekly MACD remains bullish, while the weekly RSI is bearish, indicating mixed signals. The Bollinger Bands show a mildly bullish stance on the weekly chart and bullish on the monthly. Daily moving averages are bullish, but the KST and OBV on the weekly are mildly bearish, suggesting some caution. In terms of performance, the stock has returned 30.12% over the past month compared to the S&P 500's 4.15%, and a remarkable 209.18% year-to-date versus the S&P's 14.18%. Overall, the current technical stance is mildly bullish, driven by the daily moving averages and weekly MACD, despite bearish signals from the RSI and KST....

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

As of 2 September 2025, the technical trend for Mineralys Therapeutics, Inc. has changed from mildly bullish to bullish. The current technical stance is bullish with strong indicators. The weekly MACD is bullish, and both the Bollinger Bands and Dow Theory are also indicating bullish trends. However, the weekly RSI is bearish, which suggests some caution. The daily moving averages are bullish, supporting the overall positive outlook. In terms of performance, the company has significantly outperformed the S&P 500 across multiple periods, with a 1-month return of 159.91% compared to the S&P 500's 2.33%, and a year-to-date return of 223.88% versus 12.22%....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

-382.22%

EBIT to Interest (avg)

-153.28

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.00

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

3.08

EV to EBIT

-3.51

EV to EBITDA

-3.51

EV to Capital Employed

-481.03

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-55.19%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Dow Theory

No Trend

Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 33 Schemes (11.47%)

Foreign Institutions

Held by 47 Foreign Institutions (23.35%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -5.61% vs -238.84% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-46.70",
          "val2": "-45.20",
          "chgp": "-3.32%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-43.30",
          "val2": "-41.00",
          "chgp": "-5.61%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -147.29% vs -141.28% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-192.40",
          "val2": "-84.70",
          "chgp": "-127.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-177.80",
          "val2": "-71.90",
          "chgp": "-147.29%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-46.70

-45.20

-3.32%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-43.30

-41.00

-5.61%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -5.61% vs -238.84% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-192.40

-84.70

-127.15%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-177.80

-71.90

-147.29%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -147.29% vs -141.28% in Dec 2023

All Annual Results

Company CV

About Mineralys Therapeutics, Inc.

Mineralys Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Mineralys Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Mineralys Therapeutics, Inc.?

Watch in Real-Time

What does Mineralys Therapeutics, Inc. do?

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

Is Mineralys Therapeutics, Inc. technically bullish or bearish?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Mineralys Therapeutics, Inc.

Company Coordinates